Labcorp Holdings (LH) After Investor Day And Higher Guidance Is It Fully Valued
Investor Day shifts attention to Labcorp Holdings guidance and strategy
Labcorp Holdings (LH) put its 2026 Investor Day in the spotlight as management raised full-year revenue and adjusted EPS guidance, and tied that outlook to specialty diagnostics and biopharma lab services.
Recent trading shows a mixed picture for Labcorp Holdings. The share price has climbed 13.81% over 90 days and 22.76% year to date, even though it fell 8.51% over the past month. The 1 year total shareholder return of 13.01% and 3 year total shareholder return of 57.40% suggest longer term holders have seen meaningfully stronger results than short term traders.
Scan beyond Labcorp Holdings and size up other lab and healthcare operators that are leaning into diagnostics, biopharma services, and digital tools with the hand picked 38 healthcare AI stocks
Labcorp Holdings has rerated sharply over the past year, then slipped in recent weeks as sentiment cooled. How much of that move really lines up with what this business is worth today?
Most Popular Narrative: 10% Undervalued
Against a last close of $308.95, the most followed narrative pegs Labcorp Holdings at a fair value of $344.25. This points to a modest valuation gap that hinges on specialty diagnostics and biopharma lab execution.
Labcorp Holdings continues to expand higher value specialty testing in oncology, neurology, autoimmune disease and women’s health, with this franchise now around US$2b in diagnostics revenue and a rising share of esoteric and specialty work, which supports higher revenue per patient encounter and contribution to earnings.
See why 5 investors see Labcorp Holdings as 10% undervalued.
Result: Fair Value of $344.25 (UNDERVALUED)
Still, the Labcorp Holdings story can change quickly if PAMA cuts hit harder than expected or if recent revenue and margin progress stalls again.
Find out about the key risks to this Labcorp Holdings narrative.
Next Steps
Mixed sentiment around Labcorp Holdings is clear. Consider reviewing the data for yourself and weighing both the upside and the downside using the 3 key rewards and 1 important warning sign.
Looking for more Labcorp Holdings style investment ideas?
Do not stop your research with Labcorp Holdings when a wider watchlist could surface opportunities you wish you had spotted earlier.
- Target strong fundamentals and reasonable pricing by scanning a curated set of quality candidates through the 30 high quality undervalued stocks.
- Prioritize resilience and sleep better at night by reviewing a 30 resilient stocks with low risk scores that filters for sturdier balance sheets and steadier track records.
- Get ahead of the crowd by checking a 16 high quality undiscovered gems that highlights lesser known businesses with solid underlying metrics.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com